Transapical Beating-heart Septal Myectomy in Patient With Hypertrophic Obstructive Cardiomyopathy

Recruiting N/A Interventional Study
Hypertrophic Obstructive Cardiomyopathy
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
8 and older
Sex
Any
Study type
Interventional
Purpose
Treatment
Participants needed
1,000 (estimated)
Sponsor
Xiang Wei · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

The primary purpose of this study is to evaluate the feasibility, the safety and the efficacy of the transapical beating-heart septal myectomy for the treatment of hypertrophic obstructive cardiomyopathy. This is a prospective, single-arm, single-center, first-in-man study.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: 1. Patients whose resting or provoked left ventricular outflow tract gradient \> 50 mmHg, and maximal ventricular septal wall thickness ≥ 15 mm. 2. Patients with heart function of New York Heart Association ≥ class II. 3. Patients with drug-refractory symptoms or intolerable to …
Contacts

Xiang Wei, M.D.

+8613995525956

xiangwei@tjh.tjmu.edu.cn

CONTACT

Jing Fang, M.D.

+8613296640596

jingfang@hust.edu.cn

CONTACT